Paying users zone. Data is hidden behind 
.
Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Regeneron Pharmaceuticals Inc. (REGN)
Common-Size Income Statement
Low level of difficulty
Regeneron Pharmaceuticals Inc., common-size consolidated income statement
Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).
| Income statement item | Description | The company |
|---|---|---|
| Income from operations | The net result for the period of deducting operating expenses from operating revenues. | Regeneron Pharmaceuticals Inc.’s income from operations as a percentage of revenues increased from 2016 to 2017 and from 2017 to 2018. |
| Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Regeneron Pharmaceuticals Inc.’s income before income taxes as a percentage of revenues increased from 2016 to 2017 and from 2017 to 2018. |
| Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Regeneron Pharmaceuticals Inc.’s net income as a percentage of revenues increased from 2016 to 2017 and from 2017 to 2018. |